Hematology Flashcards
1
Q
Lab test to help distinguish coagulopathy of liver disease from DIC
A
Factor VIII level
MKSAP 20
2
Q
Hemoglobin transfusion threshold for most patients
A
<7 g/dL
MKSAP 20
3
Q
Medication and dosing frequency for iron therapy
A
Once-daily or alternate-day ferrous sulfate
MKSAP 20
4
Q
MDS gold standard diagnostic test
A
Bone marrow biopsy
MKSAP 20
5
Q
Indications for a transfusion threshold >7 g/dL
A
ACS, acute stroke, hemodynamic instability, active bleeding
MKSAP 20
6
Q
Treatment of CKD-related anemia
A
Erythropoietin
MKSAP 20
7
Q
Optimal evaluation of lytic bone lesions in MM
A
MRI or PET
MKSAP 20
8
Q
Erythrocyte index correlating with uniformity or variability in erythrocyte size
A
RDW
MKSAP 20
9
Q
Decision support tool for suspected TTP management while ADAMTS13 level pending
A
PLASMIC score
MKSAP 20
10
Q
Management of anemia of inflammation
A
Treat underlying cause
MKSAP 20
11
Q
Transfusion therapy for ACS and ARDS in SCD
A
Exchange transfusion
MKSAP 20
12
Q
Microcytosis, normal RDW, normal or increased erythrocyte count
A
Thalassemia
MKSAP 20
13
Q
Dabigatran reversal agent
A
Idarucizumab
MKSAP 20
14
Q
Initial decision support tool in evaluating low-risk PE
A
PERC
MKSAP 20
15
Q
Treatment of SCD with frequent pain events, severe symptomatic anemia, previous ACS, or stroke
A
Hydroxyurea
MKSAP 20
16
Q
Curative treatment for myelofibrosis
A
Allogeneic HSCT
MKSAP 20
17
Q
Unprovoked VTE treatment duration
A
> 6 months
MKSAP 20
18
Q
Vitamin K deficiency–related coagulation profile
A
Elevated PT, normal or mildly elevated aPTT
MKSAP 20
19
Q
Hemochromatosis screening tests
A
Transferrin saturation, serum ferritin
MKSAP 20
20
Q
Agglutinated erythrocytes, DAT showing C3
A
Cold agglutinin disease
MKSAP 20
21
Q
Hemolytic anemia, bite cells, Heinz bodies
A
G6PD deficiency
MKSAP 20
22
Q
Initial treatment of chronic-phase CML
A
TKI
MKSAP 20
23
Q
Cold agglutinin disease treatment
A
Rituximab
MKSAP 20
24
Q
Most common cause of classic HUS
A
Shiga toxin–producing E. coli
MKSAP 20
25
Outpatient therapy for acute low-risk PE
Apixaban, rivaroxaban
| MKSAP 20
26
Pancytopenia, severe bone marrow hypocellularity
Aplastic anemia
| MKSAP 20
## Footnote
Aplastic anemia is characterized by the failure of the bone marrow to produce sufficient blood cells.
27
Autoimmune gastritis and intrinsic factor deficiency causing vitamin B12 deficiency
Pernicious anemia
| MKSAP 20
## Footnote
Pernicious anemia is an autoimmune condition that affects the absorption of vitamin B12.
28
Management of porphyria cutanea tarda
Phlebotomy
| MKSAP 20
## Footnote
Phlebotomy is often used to reduce iron overload in patients with porphyria cutanea tarda.
29
Anticoagulation for distal DVT without symptoms or risk factors for extension
None
| MKSAP 20
## Footnote
In cases of distal DVT without symptoms or risk factors, anticoagulation may not be necessary.
30
Duration of smoking-induced neutrophilia following smoking cessation
≥1 year
| MKSAP 20
## Footnote
Neutrophil levels may remain elevated for at least one year after quitting smoking.
31
Oral therapy for HIT
DOAC (e.g., rivaroxaban)
| MKSAP 20
## Footnote
Direct oral anticoagulants (DOACs) like rivaroxaban are used for treating heparin-induced thrombocytopenia (HIT).
32
Management of warfarin over-anticoagulation, INR >10, no bleeding
Stop warfarin, give oral vitamin K
| MKSAP 20
## Footnote
This is the recommended approach for managing significant over-anticoagulation without bleeding.
33
Evaluation of PE in patients with contraindication to IV contrast
V/Q scan
| MKSAP 20
## Footnote
A ventilation-perfusion (V/Q) scan is used to evaluate pulmonary embolism when IV contrast cannot be administered.
34
Symptomatic hyperviscosity treatment
Therapeutic apheresis
| MKSAP 20
## Footnote
Therapeutic apheresis is used to reduce blood viscosity in symptomatic patients.
35
Duration of VTE prophylaxis in pregnant person with SCD
While hospitalized and 6 weeks postpartum
| MKSAP 20
## Footnote
VTE prophylaxis is crucial for pregnant individuals with sickle cell disease during and after hospitalization.
36
Transfusion for warm autoimmune hemolytic anemia without crossmatch compatible blood
ABO- and Rh-matched transfusion
| MKSAP 20
## Footnote
In cases of warm autoimmune hemolytic anemia, it is important to use ABO- and Rh-matched blood for transfusion.
37
Two main causes of kidney disease in MM
Hypercalcemia and cast nephropathy
| MKSAP 20
## Footnote
Multiple myeloma can lead to kidney disease primarily due to hypercalcemia and cast nephropathy.
38
HIT therapy duration with documented thromboembolic event
At least 3 months
| MKSAP 20
## Footnote
Patients with HIT and a thromboembolic event require at least three months of therapy.
39
Noncardiogenic pulmonary edema 6 hours after transfusion
TRALI
| MKSAP 20
## Footnote
Transfusion-related acute lung injury (TRALI) can occur shortly after blood transfusion.
40
Preoperative management of patient with SCD for surgery requiring general anesthesia
Simple transfusion with target hemoglobin 10 g/dL
| MKSAP 20
## Footnote
This approach helps reduce the risk of complications during surgery.
41
Confirms folate deficiency when serum folate level is normal
Elevated serum homocysteine level
| MKSAP 20
## Footnote
Elevated homocysteine can indicate folate deficiency even when serum folate is within normal limits.
42
Treatment of DIC-related hypofibrinogenemia
Cryoprecipitate
| MKSAP 20
## Footnote
Cryoprecipitate is used to manage low fibrinogen levels in disseminated intravascular coagulation (DIC).
43
MM preferred treatment
Autologous HSCT
| MKSAP 20
## Footnote
Autologous hematopoietic stem cell transplantation is a preferred treatment for multiple myeloma.
44
Risk factors for upper extremity DVT
Central venous catheter, malignancy
| MKSAP 20
## Footnote
These factors significantly increase the risk of developing upper extremity deep vein thrombosis.
45
IgM paraprotein, hyperviscosity
Waldenström macroglobulinemia
| MKSAP 20
## Footnote
Waldenström macroglobulinemia is characterized by elevated IgM levels leading to hyperviscosity.
46
Safe ITP platelet count during pregnancy
>30,000/µL (30 × 10^9/L)
| MKSAP 20
## Footnote
A platelet count above this threshold is considered safe in pregnant patients with immune thrombocytopenic purpura (ITP).
47
Treatment of pre-eclampsia–related thrombocytopenia
Delivery
| MKSAP 20
## Footnote
The definitive treatment for thrombocytopenia related to pre-eclampsia is delivery of the baby.
48
Increased infection risk in hereditary hemochromatosis
Vibrio vulnificus and Yersinia enterocolitica
| MKSAP 20
## Footnote
Individuals with hereditary hemochromatosis are at increased risk for infections from these organisms.
49
Fever, tachypnea, hypoxia, cough, dyspnea, pulmonary infiltrates in patients with SCD
ACS
| MKSAP 20
## Footnote
Acute chest syndrome (ACS) is a serious complication in sickle cell disease characterized by these symptoms.
50
Isolated mild asymptomatic neutropenia in a patient of African descent
Duffy-null associated neutrophil count
| MKSAP 20
## Footnote
This condition can be a benign variant seen in some individuals of African descent.
51
Confirms vitamin B12 deficiency when cobalamin level is borderline
Elevated serum methylmalonic acid level
| MKSAP 20
## Footnote
Methylmalonic acid (MMA) is a marker that helps in the diagnosis of vitamin B12 deficiency.
52
Treatment to shorten recovery time in drug-induced neutropenia with active infection
G-CSF
| MKSAP 20
## Footnote
G-CSF stands for granulocyte colony-stimulating factor, which stimulates the production of white blood cells.
53
Treatment of MM-related hypogammaglobulinemia and recurrent infections
IVIG
| MKSAP 20
## Footnote
IVIG stands for intravenous immunoglobulin, which provides antibodies to help fight infections.
54
Microcytic anemia, increased hemoglobin A2 and F
β-Thalassemia minor
| MKSAP 20
## Footnote
β-Thalassemia minor is a genetic blood disorder that affects hemoglobin production.
55
Prolonged aPTT, low factor VIII, no correction with mixing study
Acquired hemophilia
| MKSAP 20
## Footnote
Acquired hemophilia is often associated with autoimmune disorders and can lead to significant bleeding.
56
MGUS with unexplained kidney disease
Monoclonal gammopathy of renal significance
| MKSAP 20
## Footnote
MGUS stands for monoclonal gammopathy of undetermined significance, which can lead to renal complications.
57
Mucocutaneous bleeding, normal platelet count and coagulation tests
Qualitative platelet disorder
| MKSAP 20
## Footnote
This condition indicates a dysfunction in platelet function rather than quantity.
58
DOAC for patients receiving dialysis
Apixaban
| MKSAP 20
## Footnote
Direct oral anticoagulants (DOACs) like apixaban are often preferred for their safety profile in renal impairment.
59
Macrocytic anemia, malnutrition, alcohol use disorder
Folate deficiency
| MKSAP 20
## Footnote
Folate deficiency is a common cause of macrocytic anemia and can be exacerbated by alcohol use.
60
Post-DVT pain, edema, stasis dermatitis
Postthrombotic syndrome
| MKSAP 20
## Footnote
Postthrombotic syndrome can occur after deep vein thrombosis and lead to chronic pain and swelling.
61
Hemolytic anemia, spherocytes, positive DAT
Warm autoimmune hemolytic anemia
| MKSAP 20
## Footnote
Warm autoimmune hemolytic anemia is characterized by spherocytes in the blood and a positive direct antiglobulin test (DAT).
62
Most common indications for autologous HSCT
Multiple myeloma, relapsed aggressive lymphoma
| MKSAP 20
## Footnote
Autologous hematopoietic stem cell transplantation (HSCT) is often used in these hematologic malignancies.
63
Lab test to diagnose PNH
Flow cytometry (demonstrates loss of CD55 and CD59)
| MKSAP 20
## Footnote
PNH stands for paroxysmal nocturnal hemoglobinuria, and flow cytometry helps identify affected cells.
64
Concomitant anticoagulant duration with warfarin for acute VTE
At least 5 days and therapeutic INR at least 24 hours
| MKSAP 20
## Footnote
Venous thromboembolism (VTE) treatment often requires bridging with anticoagulants before achieving therapeutic INR.
65
Erythrocytosis, positive JAK2
Polycythemia vera
| MKSAP 20
## Footnote
Polycythemia vera is a myeloproliferative disorder characterized by increased red blood cell mass.
66
SCD-related pulmonary vascular complication of pregnancy
Pulmonary hypertension
| MKSAP 20
## Footnote
Sickle cell disease (SCD) can lead to various complications, including pulmonary hypertension, especially during pregnancy.
67
Aminotransferase elevation, arthritis of the 2nd and 3rd metacarpophalangeal joints
Hereditary hemochromatosis
| MKSAP 20
## Footnote
Hereditary hemochromatosis can cause liver damage and joint issues due to iron overload.
68
Mild, asymptomatic thrombocytopenia late in pregnancy
Gestational thrombocytopenia
| MKSAP 20
## Footnote
Gestational thrombocytopenia is common and usually resolves after delivery.
69
Therapy for primary HES with PDGFR-α or -β variant
Imatinib
| MKSAP 20
## Footnote
Imatinib is a targeted therapy used for certain hematologic malignancies and conditions like hypereosinophilia syndrome (HES).
70
Lab finding of citrate toxicity during massive transfusion
Hypocalcemia
| MKSAP 20
## Footnote
Citrate, used as an anticoagulant in blood products, can bind calcium, leading to hypocalcemia.
71
Less invasive tissue biopsy site for systemic amyloidosis
Abdominal fat pad
| MKSAP 20
## Footnote
An abdominal fat pad biopsy is a common and effective method for diagnosing systemic amyloidosis.
72
Prophylactic therapy for hemophilia A
Emicizumab
| MKSAP 20
## Footnote
Emicizumab is a bispecific monoclonal antibody that mimics the function of factor VIII in hemophilia A patients.
73
PV therapy for patients intolerant of first-line agents
Ruxolitinib
| MKSAP 20
## Footnote
Ruxolitinib is a JAK1/JAK2 inhibitor used in polycythemia vera for patients who cannot tolerate conventional therapies.
74
Genetic testing for abdominal thrombosis, splenomegaly, portal hypertension
JAK2
| MKSAP 20
## Footnote
JAK2 mutations are commonly associated with myeloproliferative neoplasms, including conditions leading to thrombosis.
75
Testing indicated for moderate- to high-probability Wells score for DVT and PE
Duplex imaging for DVT; CT angiography for PE
| MKSAP 20
## Footnote
The Wells score helps stratify the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), guiding diagnostic imaging.
76
Inherited cause of mucosal bleeding; normal PT, aPTT, and platelets
vWD
| MKSAP 20
## Footnote
von Willebrand Disease (vWD) is characterized by a deficiency in von Willebrand factor, which is crucial for platelet adhesion.
77
Cancer screening with unprovoked VTE
Age- and sex-appropriate screening
| MKSAP 20
## Footnote
Unprovoked venous thromboembolism (VTE) may indicate an underlying malignancy that requires thorough screening.
78
Monoclonal protein <3 g/dL, clonal plasma cells <10% of marrow cellularity, no end-organ damage
MGUS
| MKSAP 20
## Footnote
Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condition to multiple myeloma.
79
Additional testing in most patients with thrombocytopenia and low 4T score
None
| MKSAP 20
## Footnote
The 4T score helps assess the probability of heparin-induced thrombocytopenia (HIT).
80
Treatment of asymptomatic ET in older patients
Hydroxyurea and low-dose aspirin
| MKSAP 20
## Footnote
Essential thrombocythemia (ET) management aims to reduce thrombotic risk.
81
AL amyloidosis preferred treatment
Autologous HSCT
| MKSAP 20
## Footnote
Autologous hematopoietic stem cell transplantation (HSCT) is the preferred treatment for eligible patients.
82
Ineffective hematopoiesis, hypercellular marrow, peripheral cytopenia, normal vitamin B12 and folate
MDS
| MKSAP 20
## Footnote
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis leading to cytopenias.
83
PCD with monoclonal protein exceeding limit for MGUS, no other symptoms, no end-organ damage
Smoldering MM
| MKSAP 20
## Footnote
Smoldering multiple myeloma (MM) indicates a higher risk of progression compared to MGUS.
84
Emergent reversal of unfractionated heparin
Protamine sulfate
| MKSAP 20
## Footnote
Protamine sulfate is used to neutralize the anticoagulant effects of heparin.
85
Effect of known inherited thrombophilia on acute VTE management
None
| MKSAP 20
## Footnote
Known inherited thrombophilias do not alter the immediate management of acute venous thromboembolism.
86
Optimal therapy for severe aplastic anemia in younger patients
Allogeneic HSCT
| MKSAP 20
## Footnote
Allogeneic hematopoietic stem cell transplantation (HSCT) is preferred for younger patients due to better outcomes.
87
Management of hemophilia A, minor bleeding
Desmopressin
| MKSAP 20
## Footnote
Desmopressin is used to increase factor VIII levels in patients with hemophilia A.
88
Eosinophilia and end-organ damage
HES
| MKSAP 20
## Footnote
Hypereosinophilic syndrome (HES) is characterized by eosinophilia and damage to various organs.
89
Management of life-threatening bleeding in patients taking oral Xa inhibitors
Four-factor PCC or andexanet alfa
| MKSAP 20
## Footnote
Prothrombin complex concentrate (PCC) and andexanet alfa are used for reversal of anticoagulation.
90
Initial evaluation of suspected platelet dysfunction
Platelet function analyzer
| MKSAP 20
## Footnote
Platelet function analyzers assess the functional capacity of platelets.
91
Posttransfusion dyspnea, elevated CVP, elevated BNP
TACO
| MKSAP 20
## Footnote
Transfusion-associated circulatory overload (TACO) can occur after blood transfusions, leading to respiratory distress.
92
Management of ITP with severe thrombocytopenia and bleeding
Glucocorticoids with or without IVIG
| MKSAP 20
## Footnote
Immune thrombocytopenic purpura (ITP) treatment may include glucocorticoids and intravenous immunoglobulin (IVIG) for severe cases.
93
Normochromic, normocytic anemia; elevated ferritin; low iron and TIBC
Anemia of inflammation
| MKSAP 20
## Footnote
Anemia of inflammation occurs due to chronic disease and is characterized by normal iron stores but impaired utilization.
94
Target hemoglobin level for ESA treatment in ESKD
10-11 g/dL
| MKSAP 20
## Footnote
Erythropoiesis-stimulating agents (ESAs) are used to manage anemia in end-stage kidney disease (ESKD).
95
Management of type I HIT
No further testing or therapy
| MKSAP 20
## Footnote
Type I HIT is generally mild and resolves without intervention.
96
TTP treatment
Plasma exchange, glucocorticoids, rituximab
| MKSAP 20
## Footnote
Thrombotic thrombocytopenic purpura (TTP) requires urgent treatment to prevent complications.
97
Treatment of complement-mediated HUS
Eculizumab
| MKSAP 20
## Footnote
Eculizumab is a complement inhibitor used in atypical hemolytic uremic syndrome (HUS).
98
Iron overload, cutaneous blisters, hypertrichosis
Porphyria cutanea tarda
| MKSAP 20
## Footnote
Porphyria cutanea tarda is associated with hepatic iron overload and skin manifestations.
99
Thrombocytopenia, prolonged aPTT and PT, elevated INR, hypofibrinogenemia, and elevated D-dimer level
DIC
| MKSAP 20
## Footnote
Disseminated intravascular coagulation (DIC) is a complex disorder often secondary to severe conditions.
100
Most common cause of iron deficiency in men and postmenopausal women
GI blood loss
| MKSAP 20
## Footnote
Gastrointestinal bleeding is the leading cause of iron deficiency anemia in these populations.
101
Treatment of acute proximal DVT or PE when anticoagulation is contraindicated
Retrievable or temporary IVC filter
| MKSAP 20
## Footnote
IVC stands for inferior vena cava, and filters are used to prevent blood clots from reaching the lungs.
102
VTE prevention in high-risk APLAS
Warfarin
| MKSAP 20
## Footnote
APLAS refers to antiphospholipid syndrome, a condition that increases the risk of blood clots.
103
Management of hemophilia A, active bleeding, high titer inhibitor
Activated factor VII
| MKSAP 20
## Footnote
This treatment is used because traditional factor VIII replacement is ineffective in the presence of inhibitors.
104
Skin, GI, and liver injury following allogeneic HSCT
Graft-versus-host disease
| MKSAP 20
## Footnote
Allogeneic HSCT refers to allogeneic hematopoietic stem cell transplantation, where donor cells attack the recipient's tissues.
105
Management of asymptomatic ITP and platelet count 35,000/μL (30 × 10^9/L)
Observation
| MKSAP 20
## Footnote
ITP stands for immune thrombocytopenic purpura, a condition characterized by low platelet counts.
106
MDS therapy that reduces transfusion requirements and AML conversion risk
Hypomethylating agent (azacytidine or decitabine)
| MKSAP 20
## Footnote
MDS refers to myelodysplastic syndromes, which can progress to acute myeloid leukemia (AML).
107
Secondary iron overload treatment
Iron chelation
| MKSAP 20
## Footnote
This treatment helps remove excess iron from the body, often necessary in patients with repeated blood transfusions.
108
Episodic hemolysis, marrow aplasia, unusual site of thrombosis, erythrocytes lacking CD55 and CD59
PNH
| MKSAP 20
## Footnote
PNH stands for paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
109
Pancytopenia, promyelocytes, and DIC
Acute promyelocytic leukemia
| MKSAP 20
## Footnote
DIC stands for disseminated intravascular coagulation, a serious condition associated with this type of leukemia.
110
Common causes of vitamin K deficiency
Malnutrition, prolonged antibiotics
| MKSAP 20
## Footnote
Vitamin K is crucial for blood clotting, and its deficiency can lead to bleeding problems.
111
Treatment of factor VIII inhibitor–related bleeding
Activated factor VII, activated PCC, or recombinant porcine factor VIII
| MKSAP 20
## Footnote
PCC stands for prothrombin complex concentrate, used in the management of bleeding in hemophilia.
112
Monoclonal B lymphocytes, no other clinical features to suggest CLL
Monoclonal B-cell lymphocytosis
| MKSAP 20
## Footnote
CLL stands for chronic lymphocytic leukemia, but this condition represents an early stage or benign form.
113
Infectious cause of aplastic anemia
Parvovirus B19
| MKSAP 20
## Footnote
This virus can suppress bone marrow function, leading to decreased blood cell production.
114
Supplement to increase iron absorption
Vitamin C
| MKSAP 20
## Footnote
Vitamin C enhances the absorption of non-heme iron from plant sources.
115
Warfarin-related life-threatening bleeding treatment
Four-factor PCC
| MKSAP 20
## Footnote
This treatment provides the necessary clotting factors to reverse the effects of warfarin.
116
Management of liver disease, hypofibrinogenemia, active bleeding
Cryoprecipitate
| MKSAP 20
## Footnote
Cryoprecipitate is rich in clotting factors, especially fibrinogen, which is crucial in bleeding scenarios.
117
Deficiency causing heparin resistance and VTE
Antithrombin deficiency
| MKSAP 20
## Footnote
Antithrombin is a protein that helps regulate blood clotting, and its deficiency can lead to thrombotic events.
118
Malabsorption-related iron deficiency treatment
Parenteral iron
| MKSAP 20
## Footnote
Parenteral iron is administered via injection or infusion, bypassing the gastrointestinal tract.
119
Cause of pseudothrombocytopenia
Platelet clumping
| MKSAP 20
## Footnote
This phenomenon can lead to falsely low platelet counts in laboratory tests.
120
Microcytic anemia, normal hemoglobin electrophoresis, normal iron level
α-Thalassemia trait
| MKSAP 20
## Footnote
This genetic condition affects the production of hemoglobin and is often asymptomatic.
121
Mechanical causes of acquired vWD
Prosthetic heart valves, native valvular disease, LVAD
| MKSAP 20
## Footnote
vWD stands for von Willebrand disease, which can be exacerbated by mechanical factors.
122
Low hemoglobin level with indirect hyperbilirubinemia, elevated lactate dehydrogenase, low haptoglobin
Hemolytic anemia
| MKSAP 20
## Footnote
These lab findings are indicative of increased destruction of red blood cells.
123
Lab testing diagnostic of inherited hemophilia A or B
Prolonged aPTT (corrects with mixing study), normal PT and CBC
| MKSAP 20
## Footnote
aPTT stands for activated partial thromboplastin time, a test used to assess blood coagulation.
124
Treatment of massive PE with shock
Thrombolytic therapy
| MKSAP 20
## Footnote
Thrombolytic therapy is used to dissolve blood clots quickly in emergency situations.
125
Hemolysis, thrombocytopenia, ADAMTS13 deficiency
TTP
| MKSAP 20
## Footnote
TTP stands for thrombotic thrombocytopenic purpura, a serious condition characterized by microangiopathic hemolytic anemia and thrombocytopenia.
126
Acute promyelocytic leukemia treatment
All-trans retinoic acid
| MKSAP 20
127
Chronic hemolytic anemia, spherocytes, negative DAT
Hereditary spherocytosis
| MKSAP 20
128
Hypercalcemia, kidney failure, anemia, bone lesions, rouleaux formation
MM
| MKSAP 20
129
Common deficiency causing thrombocythemia
Iron
| MKSAP 20
130
Antibiotic management of HUS
Not indicated
| MKSAP 20
131
Infectious causes of ITP
HIV, hepatitis C virus, H. pylori
| MKSAP 20
132
Type 1 vWD treatment
Desmopressin
| MKSAP 20
133
Nephrotic syndrome, cardiomegaly, macroglossia
Systemic amyloidosis
| MKSAP 20
134
Confirmatory test for HIT when EIA is positive
Serotonin release or heparin-induced platelet aggregation assay
| MKSAP 20
135
Factor inhibitor evaluation in patients with prolonged aPTT
Mixing study
| MKSAP 20
136
5q− MDS treatment
Lenalidomide
| MKSAP 20
137
Predisposing condition for warfarin-related skin necrosis
Protein C deficiency
| MKSAP 20
138
Settings in which warfarin preferred to DOAC for acute VTE therapy
Prosthetic heart valve, high-risk APLAS
| MKSAP 20
139
Hematologic complication of testosterone supplementation
Erythrocytosis
| MKSAP 20
140
Lenalidomide unique toxicity
VTE
| MKSAP 20
141
Hereditary hemochromatosis treatment
Phlebotomy
| MKSAP 20
142
Adjunct to autologous HSCT and chemotherapy to prolong survival in MM
Bisphosphonate
| MKSAP 20
143
Treatment of superficial vein thrombosis with significant risk for progression
Low-dose fondaparinux
| MKSAP 20
